EXEL

Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

Tuesday, October 19, 2021 - 9:05pm

Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021 after the markets close.
  • At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

EXEL Industries expands Board of Directors to bolster commitment to CSR and sustainability

Thursday, October 14, 2021 - 5:00pm

On the 28th of September, 2021, the EXEL Industries Group Board of Directors approved the plan to enlarge the Board of Directors.

Key Points: 
  • On the 28th of September, 2021, the EXEL Industries Group Board of Directors approved the plan to enlarge the Board of Directors.
  • Therefore, the Board of Directors wishes to welcome two new Directors who will help accelerate our progress on these matters.
  • Patrick Ballu, Chairman of the Board of Directors, said: I am delighted to welcome Ella and Sonia to our Board of Directors, which will now include 43% women.
  • The EXEL Industries group is a listed family-owned company, founded and managed by Patrick Ballu and his family since 1952.

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Thursday, October 14, 2021 - 1:00pm

Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.

Key Points: 
  • Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.
  • Following the U.S. Food and Drug Administrations (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkins lymphoma (NHL).
  • View the full release here: https://www.businesswire.com/news/home/20211014005549/en/
    XL114 is the second molecule that Exelixis in-licensed from Aurigene under the companies July 2019 collaboration, option and license agreement.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021

Monday, September 20, 2021 - 4:30pm

Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX (cabozantinib) in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer (DTC).
  • COSMIC-311 was a multicenter, randomized, double-blind, placebo-controlled phase 3 pivotal trial that enrolled 258 patients at 164 sites globally.
  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
    Hemorrhage: Severe and fatal hemorrhages occurred with CABOMETYX.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Friday, September 17, 2021 - 9:23pm

The FDA approval of CABOMETYX is an important advancement for these patients who are badly in need of new treatment options.

Key Points: 
  • The FDA approval of CABOMETYX is an important advancement for these patients who are badly in need of new treatment options.
  • Dose reductions were required in 56% of patients treated with CABOMETYX, and 22% of patients required a second dose reduction.
  • We are excited about the latest approval of CABOMETYX, which will offer hope for patients with this type of thyroid cancer.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.

Exelixis Statement on the Passing of Two Senior Executives

Monday, September 6, 2021 - 6:00pm

Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., issued the following statement on behalf of the Exelixis team and the companys Board of Directors:

Key Points: 
  • Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., issued the following statement on behalf of the Exelixis team and the companys Board of Directors:
    All of us at Exelixis are deeply, deeply saddened by Giselas passing.
  • Like Gisela, Jon was a wonderful friend and colleague, and his passing is an enormous loss to all who knew him and to the Exelixis family.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September

Wednesday, September 1, 2021 - 9:05pm

H.C. Wainwright 23rd Annual Global Investment Conference: Exelixis pre-recorded session will be available on-demand beginning 7:00am EDT / 4:00am PDT on Monday, September 13, 2021.

Key Points: 
  • H.C. Wainwright 23rd Annual Global Investment Conference: Exelixis pre-recorded session will be available on-demand beginning 7:00am EDT / 4:00am PDT on Monday, September 13, 2021.
  • BofA Securities Global Healthcare Conference: Exelixis is scheduled to present at 5:35pm BST / 12:35pm EDT / 9:35am PDT on Wednesday, September 15, 2021.
  • Cantor 2021 Virtual Global Healthcare Conference: Exelixis is scheduled to present at 2:40pm EDT / 11:40am PDT on Wednesday, September 29, 2021.
  • For more information about Exelixis, please visit www.exelixis.com , follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.